SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the presentation of four posters at PEGS (The Essential Protein Engineering Summit) highlighting proof-of-concept data validating its GPCR library, antibody optimization solution to improve antibody therapeutics, and the drug discovery applicability of two types of synthetic variant libraries.
“Taken together, these data illustrate the robust power of precisely-defined synthetic libraries to explore all relevant variations for screening antibody therapeutics,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “As we continue to forward integrate, we are now able to offer our customers exceptionally high quality synthetic libraries for their internal discovery efforts and now we have proof-of-concept data for our biologics discovery platform that demonstrate the value of our GPCR library as well as our antibody optimization solution approaches.”
All posters were presented on Monday, April 8, 2019.
Poster Number: A103
The data presented demonstrate that Twist Bioscience’s massively parallel DNA synthesis platform, combined with advanced molecular biology technologies for library construction, creates more uniform and precise variant libraries than any other method for comprehensive generation and evaluation of functional and non-functional diversity for protein engineering.
Poster Number: A104
The proof-of-concept data demonstrated that our high-throughput antibody discovery platform identifies functional antibodies against GPCR targets within a few months, and can readily develop antibodies with affinities in the nanomolar range. These antibodies exhibited many modes of action to modulate GPCR activity.
Poster Number: A105
The data demonstrate that combinatorial variant libraries are powerful tools that accelerate the exploration of the large variant space in antibody engineering, pathway engineering, and protein engineering. The poster highlights Twist Bioscience’s ability to construct complex high-diversity libraries at confined regions (i.e. CDRs), and introduce technology advancements to enable the construction of synthetic DNA libraries with diversity scattered along the length of the construct to home in on the target of interest.
Poster Number: A106
Rapid Optimization and Humanization of an Anti-PD1 Antibody
The proof-of-concept data showed that our antibody optimization software successfully generated antibodies with similar or improved binding affinity when compared to commercial PD-1 antibodies Keytruda and Opdivo.
About Twist Biopharma Antibody Discovery Solutions: Writing the Future of Biologics
Twist Biopharma, the biologics discovery division of Twist Bioscience, offers proprietary antibody discovery and optimization solutions through partnerships with biotechnology and pharmaceutical companies. Twist Bioscience has developed a disruptive DNA synthesis platform that “writes” DNA on a silicon chip. By leveraging its unique technology to manufacture DNA at scale, Twist is able to construct proprietary and truly unique antibody libraries precisely designed to match the sequences that occur in the human body. These “library of libraries” provide an integral resource for antibody therapeutic discovery and optimization that can be utilized by pharmaceutical and biotechnology companies. For more information, visit www.twistbiopharma.com.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential value of Twist’s libraries or its GPCR library or antibody optimization solution. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 20, 2018 and Twist Bioscience’s Form 10-Q for the quarter ended December 31, 2018 filed with the Securities and Exchange Commission on February 11, 2019. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
